AUTHOR=Zhang Hao , Chen Zhiyang , Wang Zeyu , Dai Ziyu , Hu Zhengang , Zhang Xun , Hu Min , Liu Zhixiong , Cheng Quan 

TITLE=Correlation Between APOBEC3B Expression and Clinical Characterization in Lower-Grade Gliomas

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.625838

DOI=10.3389/fonc.2021.625838

ISSN=2234-943X

ABSTRACT=Background: As the most aggressive tumors of the central nervous system, gliomas have poor prognosis with limited therapy methods. Immunotherapy has become promising in the treatment of gliomas. Here, we explored the expression pattern of APOBEC3B, a genomic alterations mutagen, in gliomas to assess its potential as an immune biomarker and target. Methods: We mined molecular data from two publicly available genomic datasets, TCGA and CGGA, to investigate the relevance between APOBEC3B and clinical characterizations including classifications, prognosis and immune infiltrating in glioma. We especially explored the correlation between APOBEC3B and tumor mutations. Samples from Xiangya cohort were used for immunohistochemistry staining. Results: Our findings demonstrated that higher APOBEC3B expression level was shown in advanced glioma and other cancer types, which indicated poorer prognosis. APOBEC3B also stratified patients’ survival in Xiangya cohort. APOBEC3B was significantly associated with infiltrating immune and stromal cell types in tumor microenvironment. Notably, APOBEC3B was involved in tumor mutation and strongly correlated with the regulation of oncogenic genes. Conclusion: Our findings identified that APOBEC3B may be a latent molecular target in prognosis and immunotherapy of gliomas.